Search results
New EHA data reveal how badly Gilead's $4.9B bet on CD47 imploded
FierceBiotech· 12 hours agoMagrolimab showed worse performances compared with placebo across multiple efficacy and safety metrics in their respective combinations with chemotherapy, data from the ENHANCE ...
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 3 days agoProgression-free survival is how long patients live before their cancer worsens. The company added...
Ipsen drug for rare liver disease approved by FDA
BioPharma Dive via Yahoo Finance· 4 days agoThe medicine will join Intercept’s Ocaliva as a treatment option for primary biliary cholangitis. Another drug, from the now Gilead-owned CymaBay, could...
FROM THE GUT: Sweet, sweet sugar can be so very bad for our bodies
The Fredericksburg Free Lance-Star· 6 days agoAhhh sugar … how could something so sweet and pleasurable possibly be bad for us? “Sugar” is the...
Intuitive surgical EVP sells shares worth $99,567 By Investing.com
Investing.com· 4 days agoDeSantis sold a total of 239 shares at a price of $416.6 each, amounting to $99,567. The...
3 Robotics Stocks to Turn $1000 into $1 Million: June 2024
InvestorPlace· 19 hours agoMy task today is to identify three robotics stocks to buy in June that you can turn into $1 million...
Radioactive drugs strike cancer with precision
Knowable Magazine via Yahoo News· 2 days agoAt one clinic in Bad Berka, Germany, over a thousand patients were treated within a decade, showing extended survival rates compared with what’s typical...
Looking back, moving forward: How hospitality trends are evolving | By Lionel Saul and Tatyana...
Hospitality Net· 5 days agoLast year, we explored eight dynamic hospitality trends shaping our industry. Exchange rate...
Seeds of change: Ernst Seeds uses data-driven approach to restore habitats - GPS World
GPS World· 2 days agoOn this 10,000-acre farm near the small town of Meadville, Pennsylvania, the company pioneered the...